» Articles » PMID: 19381054

[Inter-departmental Differences in the Eradication Therapy for Helicobacter Pylori Infection: a Single Center Study]

Overview
Specialty Gastroenterology
Date 2009 Apr 22
PMID 19381054
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Eradication rates of Helicobacter pylori (H. pylori) tend to decrease over the last few years. Apart from the antibiotic resistance and patients compliance, various factors have an influence on the efficacy of eradication therapy. We analyzed the inter-departmental differences in the eradication therapy for H. pylori infection.

Methods: Between January 2003 and June 2007, total 3,072 eradication regimens were prescribed to patients. Eradication rates according to departments - gastroenterology (GE), general internal medicine (IM) and family medicine (FM) - were analyzed retrospectively.

Results: The overall eradication rate of first-line triple therapy was 82.5% and second-line quadruple therapy was 71.2%. In the department of IM and FM, the eradication therapy was applied more frequently to the patients with erosion only, not ulcer. Overall eradication rates according to the departments were 87.0% in GE, 81.1% in IM and 77.2% in FM (p=0.02 GE vs. IM and p<0.01 GE vs. FM, respectively). Eradication rate in patients with peptic ulcer was also significantly higher in GE compared with IM or FM.

Conclusions: In primary clinic (IM and FM), the eradication therapy was frequently applied to erosion. The eradication rates of H. pylori in GE department were significantly higher than those of IM or FM. Inter-departmental differences of the eradication rate might be caused by patients' compliance to prescribed medication.

Citing Articles

Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea.

Yoon K, Park S, Lee S, Kim B, Kim J J Korean Med Sci. 2014; 29(9):1240-6.

PMID: 25246742 PMC: 4168177. DOI: 10.3346/jkms.2014.29.9.1240.


Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?.

Gong E, Yun S, Jung H, Lim H, Choi K, Ahn J J Korean Med Sci. 2014; 29(5):704-13.

PMID: 24851029 PMC: 4024949. DOI: 10.3346/jkms.2014.29.5.704.


Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.

Kim M, Kim N, Kim S, Jo H, Shin C, Park Y BMC Gastroenterol. 2013; 13:138.

PMID: 24050512 PMC: 3848835. DOI: 10.1186/1471-230X-13-138.


Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori.

Yun S, Seon H, Ok C, Yoo K, Kyung Kang M, Kim W Gut Liver. 2012; 6(4):452-6.

PMID: 23170149 PMC: 3493725. DOI: 10.5009/gnl.2012.6.4.452.